Group 1: Nanwei Technology - Nanwei Technology benefits from the explosive growth of the GLP-1 peptide drug market, leading to significant revenue growth in chromatography filler products, which drives rapid development in small molecule business [1] - The company's net profit margin increased quarter-on-quarter in Q2, primarily due to the high gross margin and substantial share of chromatography filler business [1] - Nanwei Technology aims to create a comprehensive chromatography technology platform to provide overall solutions and accelerate overseas market expansion to enhance international competitiveness [1] Group 2: Medicy - Medicy has established a research office in Boston, USA, aiming to increase overseas business share to 40-50% [2] - The company has developed a comprehensive preclinical research service capability in biopharmaceutical R&D and is building multiple biopharmaceutical R&D technology platforms [2] - Medicy's operating costs decreased by 12.46% year-on-year due to cost control measures, and the domestic CRO industry is expected to benefit from policy support for innovative drug development [2] Group 3: Naipu Mining - Naipu Mining's forged composite liners offer significant advantages, including better wear resistance and higher mill efficiency, with successful applications in Tibet's Zhinuola mine [3] - The company plans to promote forged composite liners as a leading product and has agreements with multiple mines, expecting more successful cases by the end of this year and early next year [3] - Naipu Mining has invested in a copper-gold mine project in Colombia, which has completed feasibility design and is expected to have a construction period of two years with a mine life of 14.2 years [3] Group 4: China Ruilin - China Ruilin Engineering Technology Co., Ltd. has a diverse range of core technologies in the non-ferrous metal industry, with overseas business revenue accounting for 41.02% and domestic business revenue for 58.98% in 2024 [4] - The company is progressing with fundraising projects that will enhance its R&D capabilities and core competitiveness [4] - Representative overseas projects include the Abuja water supply project in Nigeria and the expansion of the Bor copper smelting plant in Serbia [4]

Core Viewpoint - Nanwei Technology (688690) is experiencing growth driven by the booming GLP-1 peptide drug market, leading to increased investment in new drug research and production capacity by domestic and international pharmaceutical companies [2][3]. Group 1: Business Performance - The company's main revenue for Q1 2025 was 189 million yuan, a year-on-year increase of 22.39%, with a net profit attributable to shareholders of 29.22 million yuan, up 72.98% year-on-year [7]. - The gross profit margin for the chromatography filler business is high, accounting for approximately 60% of the company's revenue, which has improved overall profitability [4]. Group 2: Market Strategy - The company is focusing on the antibody new drug projects as a key area for replacing imported products, enhancing competitiveness through continuous R&D investment and product innovation [3]. - To address domestic competition, the company is building a comprehensive chromatography technology platform, providing integrated solutions to avoid price wars in single product categories [6]. Group 3: Mergers and Acquisitions - The acquisition of two instrument companies enhances the company's product line from chromatography fillers to protein purification equipment, improving business and product layout and achieving synergy in customer expansion and market sales [5]. Group 4: Future Outlook - The company is accelerating its overseas market layout and enhancing its overseas sales capabilities to increase application opportunities for its filler products among international clients [3][6].

Group 1: Company Performance - Northern Rare Earth expects a net profit of 900 million to 960 million yuan for the first half of 2025, representing a year-on-year increase of 1882.54% to 2014.71% [1] - Muyuan Foods anticipates a net profit of 10.5 billion to 11 billion yuan for the first half of 2025, reflecting a year-on-year growth of 924.6% to 973.39% [2] - Hongta Securities projects a net profit of 651 million to 696 million yuan for the first half of 2025, indicating a year-on-year increase of 45% to 55% [3] Group 2: Business Developments - Dazhihui clarifies that it has not engaged in businesses related to "stablecoins," "virtual asset trading," or "cross-border payments," following a significant stock price fluctuation [4] - Bluetech announces a share transfer agreement where its actual controller will change, with the Ma'anshan Municipal Government becoming the actual controller after the transfer of 18% of shares [5] Group 3: Industry Trends - Jiangsu Electric Power reports a 5.01% year-on-year increase in electricity generation for the first half of 2025 [6] - Jin'an Guoji anticipates a non-recurring net profit growth of 4700% to 6300% for the first half of 2025 [6] - New Beiyang expects a non-recurring net profit growth of 650% to 720% for the first half of 2025 [6]

Group 1 - Morning Light Biological expects a net profit of 202.0 million to 232.0 million yuan for the first half of 2025, representing a year-on-year increase of 102.33% to 132.38% [1] - Northern Rare Earth anticipates a net profit of 900.0 million to 960.0 million yuan for the first half of 2025, with a significant year-on-year growth of 1882.54% to 2014.71% [1] - Youfa Group forecasts a net profit of 277.0 million to 307.0 million yuan for the first half of 2025, reflecting a year-on-year increase of 151.69% to 178.93% [1] Group 2 - Torch Electronics projects a net profit of approximately 247.0 million to 280.0 million yuan for the first half of 2025, indicating a year-on-year growth of 50.36% to 70.45% [3] - Zhiwei Intelligent expects a net profit of 91.98 million to 112.43 million yuan for the first half of 2025, with a year-on-year increase of 62.85% to 99.06% [4] - Youhao Group anticipates a net profit of 12.0 million yuan for the first half of 2025, representing a year-on-year growth of 51% [5] Group 3 - Nami Technology expects a net profit of 61.0 million to 73.0 million yuan for the first half of 2025, with a year-on-year increase of 35% to 62% [7] - Xinda Co. forecasts a net profit of 130.0 million to 150.0 million yuan for the first half of 2025, reflecting a substantial year-on-year growth of 2443.43% to 2834.73% [8] Group 4 - Shaanxi Coal Industry reported a coal production of 14.36 million tons in June, a year-on-year decrease of 5.07% [9] - Huanxu Electronics announced a consolidated revenue of 4.587 billion yuan in June, a year-on-year decline of 1.23% [10] Group 5 - Huadian International successfully issued 2.0 billion yuan in medium-term notes with a maturity of 3+N years and a coupon rate of 1.89% [20] - Zhongmin Energy reported a total power generation of 1.405 billion kilowatt-hours in the first half of 2025, a year-on-year decrease of 0.89% [20] Group 6 - Huaxia Biotech passed the FDA inspection with zero deficiencies, covering six major systems [21] - Ruikeda's application for convertible bond issuance has been accepted by the Shanghai Stock Exchange [22] Group 7 - Dafu Technology plans to invest no more than 100 million yuan in Anhui Yunta [42] - Tongda Co. won a bid for a project valued at 180.3 million yuan from the Southern Power Grid [46]

[Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%83%85%E5%86%B5) The company anticipates significant performance growth in H1 2025, with revenue projected to increase by 18-24% and net profit attributable to shareholders by 35-62% H1 2025 Performance Forecast vs. Prior Year Comparison | Indicator | H1 2025 Forecast (CNY Millions) | H1 2024 Officially Disclosed (CNY Millions) | Year-over-Year Growth Rate | | :--- | :--- | :--- | :--- | | **Operating Revenue** | 400 - 420 | 339.77 | 18% - 24% | | **Net Profit Attributable to Parent** | 61 - 73 | 45.05 | 35% - 62% | | **Net Profit Attributable to Parent (Excluding Non-Recurring Items)** | 55 - 65 | 36.54 | 51% - 78% | - These performance forecast figures are preliminary estimates by the company's finance department and have not been audited by a certified public accountant[2](index=2&type=chunk) [Prior Year Performance Review](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8A%E5%B9%B4%E5%90%8C%E6%9C%9F%E4%B8%9A%E7%BB%A9%E6%83%85%E5%86%B5) This section presents H1 2024 performance as a comparative baseline, including operating revenue of approximately CNY 340 million and net profit attributable to parent of CNY 45.05 million H1 2024 Performance Overview | Indicator | Amount (CNY Millions) | | :--- | :--- | | **Operating Revenue** | 339.77 | | **Net Profit Attributable to Parent Company Shareholders** | 45.05 | | **Net Profit Attributable to Parent Company Shareholders (Excluding Non-Recurring Items)** | 36.54 | [Key Drivers of Current Period Performance Change](index=1&type=section&id=%E4%B8%89%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8C%96%E7%9A%84%E4%B8%BB%E8%A6%81%E5%8E%9F%E5%9B%A0) Performance growth is primarily driven by the company's focus on core business, enhanced marketing, and product innovation, leading to approximately 20% sales growth in key products - The company focused on its core separation, purification, and analytical testing businesses, continuously strengthening marketing, application technology development, and product iteration and innovation[4](index=4&type=chunk)[5](index=5&type=chunk) - Core businesses, including chromatographic packing and media products, achieved approximately **20% sales revenue growth** in the first half, significantly contributing to performance improvement[5](index=5&type=chunk) [Risk Warning](index=2&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company confirms no significant uncertainties have been identified that could impact the accuracy of this performance forecast - The company has not identified any significant uncertainties affecting the accuracy of this performance forecast[6](index=6&type=chunk) [Other Explanatory Matters](index=2&type=section&id=%E4%BA%94%E3%80%81%E5%85%B6%E4%BB%96%E8%AF%B4%E6%98%8E%E4%BA%8B%E9%A1%B9) Investors are reminded that the disclosed data are preliminary, and final financial figures will be based on the official H1 2025 report, with investment risks noted - The forecast data provided are preliminary, and specific financial figures will be subject to the company's officially disclosed H1 2025 report[7](index=7&type=chunk)

Core Viewpoint - Suzhou Nanwei Technology Co., Ltd. has announced the adjustment of the implementation subject for granting employee stock ownership platform shares to incentivize high-end talent and core employees [1][2][3] Group 1: Granting Employee Stock Ownership - The company plans to grant a total of 1,817,848.42 yuan worth of shares, corresponding to 3,289,440 shares, to 26 incentive targets [1] - The original holding platform subjects, Suzhou Nayan and Suzhou Nazhuo, faced limitations due to the number of partners, leading to the establishment of a new partnership, Suzhou Industrial Park Nayu Management Consulting Partnership [2] Group 2: Impact of Adjustments - The adjustment of the implementation subject for granting employee stock ownership will not have a substantial impact on the company's financial status and operating results [2] - The adjustment complies with relevant laws and regulations and does not harm the interests of the company and its shareholders [2][3] Group 3: Review Procedures and Opinions - The adjustment was approved during the third board meeting held on June 30, 2025 [2] - The Compensation and Assessment Committee confirmed that the adjustment aligns with the Shanghai Stock Exchange's regulations and the revised employee stock ownership plan [2] - The Supervisory Board also agreed that the adjustment followed the necessary review and disclosure procedures, ensuring no harm to shareholder interests [3]

根据公司2022年第三次临时股东大会批准修订的《员工股权激励计划》，为 引进高端人才和专家资源、激励部分核心员工，2022年9月22日召开的第二届董 事会第十五次会议，审议通过《关于向激励对象授予员工持股平台财产份额的议 案》，决定向牟一萍、赵顺、金百胜等26名激励对象授予员工持股平台合计 2,376,006.31元的财产份额（对应公司股份4,299,440股,占公司总股本的 1.07%），其中苏州纳研管理咨询合伙企业（有限合伙）（以下简称"苏州纳 研"）的授予份额为1,817,848.42元（对应公司股份3,289,440股）；苏州纳卓 管理咨询合伙企业（有限合伙）（以下简称"苏州纳卓"）的授予份额为 558,157.89元（对应公司股份1,010,000股）。该财产份额授予后通过持股平台 苏州纳卓和苏州纳研的执行事务合伙人苏州纳百管理咨询有限公司（以下简称 "苏州纳百"）向激励对象转让方式完成。 二、向激励对象授予员工持股平台财产份额的进展情况 因原定授予财产份额的持股平台主体苏州纳研和苏州纳卓的合伙人人数限 制，为顺利推进上述向激励对象授予员工持股平台财产份额事项，公司决定由苏 州纳百与被授予的26名激 ...

中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为苏州纳 微科技股份有限公司（以下简称"纳微科技"或"公司"）首次公开发行股票并 在科创板上市的持续督导保荐人，根据《证券发行上市保荐业务管理办法》《上 市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对公司首 次公开发行股票部分募投项目结项并将节余募集资金永久补充流动资金及部分 募投项目延期事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2021 年 4 月 21 日出具的《关于同意苏州纳微科技股份有限公司首次公开发行股票注册的批 复》（证监许可〔2021〕1395 号），公司首次向社会公开发行人民币普通股（A） 股 4,400 万股，每股发行价格为 8.07 元，募集资金总额为人民币 35,508.00 万元； 扣除发行费用后实际募集资金净额为人民币 30,793.61 万元。上述募集资金已于 2021 年 6 月 18 日全部到账并经容诚会计师事务所（特殊普通合伙）对公司首次 公开发行股票的 ...

证券代码：688690 证券简称：纳微科技 公告编号：2025-022 苏州纳微科技股份有限公司 关于部分募投项目结项并将节余募集资金永久补充 流动资金及部分募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州纳微科技股份有限公司（以下简称"公司"）于2025年6月30日召开第三 届董事会第七次会议和第三届监事会第五次会议，审议通过《关于部分募投项目 结项并将节余募集资金永久补充流动资金及部分募投项目延期的议案》，同意公 司首次公开发行股票募集资金投资项目"研发中心及应用技术开发建设项目子项 目——新型磁分离介质研发项目"结项并将节余募集资金用于永久补充流动资金， 同意将募投项目"海外研发和营销中心建设项目"达到预定可使用状态的时间延 期至2026年6月。本次部分募投项目延期仅涉及项目进度的变化，未改变募投项目 的投资内容、投资总额、实施主体，不会对募投项目的实施造成实质性影响。 本次事项已经公司第三届董事会战略委员会审议通过，公司监事会发表了明 确同意的意见，保荐机构中信证券股份有限公司对本事项出具了 ...

主办单位： BioPlus 承办单位： 迫界生物 执行单位： 苏州盛杰 特约支持： BioBAY 分论坛联合主办： 东曜药业、播禾创新、智药局 私董会联合主办： 科百特、纳微科技、恒驭生物 支持单位： 三优生物、 Twist Bioscience、 诺纳生物、布鲁克细胞分析、康源博创、大湾生物、中新生命科学园 Biosparc 合作媒体： 医药笔记、生物世界、新耀俱乐部管理有限公司、A ntibody Research、医药速览、小药说药、新药启航、 丁香园Insight数据库、研在云 基础门票：200元； 含2天公开会议，不含餐 会议门票：500元； 含2天公开会议，2天午餐 免费门票：0元；仅开放 生物医药投资人、Biotech/药企、临床/院校科学家； 兑换码；详情咨询： Times 150 6123 2737 主题： 2025抗体Plus创新峰会 时间：6 月25-26日（周三/四） 地点： 中国 苏州工业园区中茵皇冠假日酒店 参会报名 审核制；扫描下方二维码可报名 ▼ 免费门票即将告罄！符合申请条件的观众，转发本文到朋友圈集赞30个，即可领取。 背景介绍 从1986年FDA批准第一批单克隆抗体（An ...